AzTrials
AzTrials

Self-harmSH-MARANCT05765864

Self-harm Behaviour Among the Most At-risk Adolescents

An observational study of Self-harm and Personality Disorder, Borderline, run by University of Ljubljana, Faculty of Medicine at 2 sites in Slovenia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In the proposed study, three objectives will be pursued: 1. To develop a method to identify more effectively the acute and long-term risk of adolescents with the most threatening self-harm behaviours. 2. Read more about this study

Who is it for?
Ages 13 to 18 yearsHealthy volunteers can take part
What is being tested?
Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3, Columbia Suicide Severity Rating Scale (CSSRS) and The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)
Type of treatment
Vaccines
How many people
400 participants
Where
2 sitesSlovenia
Study dates
23 Mar 2023to Oct 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: CLINICAL GROUP: * patients hospitalized in the Intensive Child and Adolescent Psychiatry Unit or the Unit for Adolescent Psychiatry of the Centre for Mental Health University Psychiatric Clinic Ljubljana * aged between 13 and 19 years. * In the case of consent, parents will also be asked for consent for those under 15 years of age. CONTROL GROUP: * 8th grade students in primary school, * 1st year students in secondary school * 1st year students in college * aged 13-19 years * Attending a regular systematic review. These scheduled regular systematic examinations are accompanied by venous blood sampling.

Who may be able to join

  • Suicidality
  • Self-harming with no intention to die
  • Age 13-19

Who cannot join

  • Confirmed acute psychotic disorder
  • Intellectual disability
  • Severe physical illness (e.g. cardiovascular or renal disease)
  • Disease of the central nervous system (e.g. encephalitis, brain injury or haemorrhage, epilepsy)
  • Acute poisoning (including with psychoactive substances)
  • CONTROL GROUP:
Show all 13Show fewer
  • Suicidality
  • Self-harming with no intention to die
  • Known mental disorder (e.g. depression, bipolar disorder, schizophrenia, intellectual disability)
  • Severe physical illness (e.g. cardiovascular or renal disease)
  • Disease of the central nervous system (e.g. encephalitis, brain injury or haemorrhage, epilepsy)
  • Acute poisoning (including with psychoactive substances)
  • Mental disorder, history of suicidality or self-injurious behaviour in a first-degree relative (a parent or a sibling).

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Maja Drobnič Radobuljac contact

maja.radobuljac@psih-klinika.si

Slovenia2 sites, 1 recruiting
  • Medical Faculty - University of Ljubljana

    Ljubljana, 1000

    Active, not recruiting
  • University Psychiatric Clinic Ljubljana

    Ljubljana, 1000

    Maja Drobnič Radobuljac, MD, PhD, 015874840 ext. +386, maja.radobuljac@mf.uni-lj.si

    Sebastijan Mihelič, 015874908 ext. +386, sebastijan.mihelic@psih-klinika.si

    Recruiting

Other trials in Slovenia

About this study

Official title: Influences on and Prevention of Self-harm Behaviour Among the Most At-risk Adolescents

In the proposed study, three objectives will be pursued:

  1. To develop a method to identify more effectively the acute and long-term risk of adolescents with the most threatening self-harm behaviours.
  2. To identify the factors that influence the risk of self-harm behaviours and the success of treatment/treatment of these behaviours in the most at-risk adolescents (changes in these factors).
  3. Develop guidelines for more effective treatment of the most at-risk adolescents.
Read more

For this purpose, a sample of approximately 200 young people who will be hospitalised for suicide risk (the most at risk in Slovenia) and an approximately equal number of healthy adolescents will be included. At inclusion, the presence of several factors will be assessed by reviewing demographic data, clinical diagnosis, self-assessment questionnaires and clinical psychological tests (CSSRS, B-NSSI-AT, ISAS, LPFS-BF2.0, BPFSC-11, TSCC, PAI, ECR-RS, DASA-YV, ASHRS), social assessment, and blood sampling for genetic analyses (DNA isolation, sequencing, nucleotide sequence recognition, quantification and evaluation of short tandem repeats, identification of methylation sites). Longitudinal tracking of autoaggressive events and heteroaggressive events during hospitalisation will be performed and recorded on an ongoing basis. The risk and protective factors of the adolescents most at risk will be compared with a control group of adolescents. The same factors will be reassessed in the most at-risk adolescents after 6 and 18 months of treatment as usual. The data will be collected in a data entry and storage system that will ensure the privacy of the data entered in accordance with the GDPR.

This will allow the investigators to identify young people at particular risk of severe self-harm behaviour more reliably, to target them for more intensive and effective treatment, and thus to improve their safety, quality of life and prognosis in the short and long term.

Read the detailed description

DESCRIPTION OF THE RESEARCH PROJECT "Influences on and prevention of self-harm behaviour among the most at-risk adolescents".

  1. Scientific background Detailed in the attached Study Protocol
  2. Detailed description of the work programme 2.1. Content and work programme The study will include a sample of approximately 200 young people who will be hospitalised for suicide risk (the most at risk in Slovenia) and an approximately equal number of healthy adolescents. At enrolment, the investigators will assess the presence of several factors by reviewing demographic data, clinical diagnosis, self-assessment questionnaires, social assessment, clinical psychological tests, rating scales and blood sampling for genetic analyses. They will longitudinally track autoaggressive events and heteroaggressive events in the patients during hospitalisation and keep a running record of them. The risk and protective factors of the most at-risk adolescents will be compared to a control group of healthy adolescents. The same factors in the most at-risk adolescents will be reassessed after 6 and 18 months of treatment. A detailed description of the study design is given in Figure 2 and Table 2 of Study Protocol.

2.2. Subjects: Subjects with inclusion and exclusion criteria are described in Table 2 (Study Protocol, WP2).

2.3. Methods: 2.3.1. Questionnaires and psychodiagnostic tools:

  1. Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3: The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.
  2. Columbia Suicide Severity Rating Scale (CSSRS).
  3. The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT).
  4. Personality Assessment Inventory-Adolescent (PAI-A).
  5. Trauma Symptom Checklist for Children (TSCC).
  6. Experiences in Close Relationships-Relationship Structures (ECR-RS).
  7. Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV).
  8. Adolescent Self-Harm Risk Scale (ASHRS): this is the scale we developed for the present study.
  9. The Level of Personality Functioning Scale-Brief Form 2.0 (LPFSBF 2.0).
  10. Lifetime Incidence of Traumatic Events questionnaire (LITE).
  11. Borderline Personality Features Scale (BPFSC-11).
  12. Inventory Of Statements About Self-Injury (ISAS).

2.3.2. Genetic methods: DNA isolation: The genomic DNA is going to be isolated according to the established laboratory protocol using FlexGene DNA kit (Qiagen Germany) and 5 mL EDTA-blood sample. Isolated DNA will be stored at 4°C.

Sequencing: Sequencing will be performed on available in-house long-read sequencing technology nanopore PromethION (Oxford Nanopore Technologies). The ability to detect DNA modifications via differences in the electric current intensity produced from a nanopore read of an unmodified base and that of a modified base, enables the detection of DNA methylation in different CpGs from human natural DNA at epigenome-wide level.

Libraries will be prepared using ligation sequencing kit (SQK-LSK 109, Oxford Nanopore Technologies) in following stages: 1. NEBNext Ultra II End repair / dA-tailing, 2. ligation of the native barcodes, 3. ligation of sequencing adapters, 4. flow cell priming and DNA library loading (Flow Cell Priming Kit, Oxford Nanopore Technologies).

The analysis will be conducted using barcoded participants' DNA, enabling the simultaneous analysis of multiple participant's, by pooling the equimolar amount of DNA into a single pool, based on the observation groups. The sample pooling will reduce the effect of individual epigenome variability and enrich the cohort-specific epigenetic signals, potentially associated with the clinical phenotype.

Bioinformatics Base Calling: From the raw sequencing signal, the nucleotide sequences will be determined using the software tool Guppy, which is based on a predictive neural network model. The identified reads and their reliability will be stored in FASTQ files. For subsequent alignments of long reads, the human genome (GRCh38) will be used as a reference.

Variant Calling: Megalodon software (Oxford Nanopore Technologies) will be utilized for determining nucleotide sequences from the raw signal, alignment of readings on human reference genome and variant calling. The reliability of the findings will be additionally confirmed using the software tool Medaka (Oxford Nanopore Technologies). The tool uses a neural network model to identify genetic variants, based on constructed consensus sequences. Variant data will be stored in VCF files.

Quantification and evaluation of short tandem repetitions: Tandem-genotypes and STRique will be used to detect changes in length of tandem repeats, from aligned long DNA reads. In addition to the aligned reads input, the software tool STRique accepts the raw sequencing signal, based on which a hidden Markov model quantifies and evaluates the likelihood of a change. The validated changes in length of tandem repeats will be stored in TSV files.

Methylation sites detection: Different methylation-calling tools will be utilized using the METEORE software tool. The reliability of the methylated CpG islands found in the results will be demonstrated by the prediction models (random forest and multiple linear regression). Additionally, the detected methylated sites will be compared with the results of the Remora software (Oxford Nanopore Technologies). The locations of reliable methylation sites will be stored in BED and TSV files.

2.4. Conduct of the research "Influences on and prevention of self-harm behaviour among the most at-risk adolescents" The detailed survey process is described in Figure 2 and Table 2 of Study Protocol.

Detailed definition of the work packages of the research "Influences on and prevention of self-harm behaviour among the most at-risk adolescents".

2.4.1. WP 1: Establishment of a working research module on "Influences on and prevention of self-harm behaviour among the most at-risk adolescents".

Lead organisation: University of Ljubljana, Faculty of Medicine and Centre for Mental Health, University Psychiatric Clinic Ljubljana (UPKL) Participating organisations: the Clinical Institute of Special Laboratory Diagnostics of the Paediatric Clinic of the UKC Ljubljana (KISLD) and the Faculty of Electrical Engineering, Computer Science and Informatics of the University of Maribor (FERI) T1: At this stage, all questionnaires were prepared in sets with the corresponding survey numbers.

  1. Enrollment kit (Screening questionnaire, CSSRS, B-NSSI-AT)
  2. Time1 kit (General Questionnaire1, PAI-A, TSCC, ECR-RS, DASA-YV, ASHRS, LPFSBF 2.0, LITE, BPFSC-11, ISAS), venous blood sample collection for genetic analyses
  3. Time2 kit (DASA-YV tracing, Incident Report (commited and prevented), General Questionnaire2)
  4. Time3 kit (General Questionnaire3, CSSRS, B-NSSI-AT, PAI-A subscales, TSCC subscales, ECR-RS, DASA-YV, ASHRS, LPFSBF 2.0, LITE, BPFSC-11), venous blood sample collection for genetic analyses.

T2: Development of a protocol for subject enrolment and data acquisition, storage and analysis. This work included the preparation of information materials for subjects and parents/guardians, informed consents/assents and a detailed protocol that will be accessible to the investigators throughout the study.

T3: Preparation of the data entry and storage system: The data entry and storage information system will be prepared so that it will enable data entry via pre-prepared templates for initial and intermediate reporting of measurements. The system will ensure data privacy, as access will be restricted to anonymized data and allowed only for the purposes of analysis (in line with the General Data Protection Regulation (EU) 2016/679 (GDPR)). The system will ensure that data is safely deleted after the project is completed (according to the GDPR). The information system will be physically located in the Republic of Slovenia, and physical access to the hardware will be limited only to administrative activities by qualified personnel.

T4: Education and training of the working group: This part will consist of several educational sessions for the different members of the working group: a. Patient involvement, involvement of pupils and students of the control group (assessment of the fulfilment of inclusion/exclusion criteria, information about the study, obtaining consent from adolescents and relatives), b. Collection of questionnaire responses, c. Collection of biological samples, d. Data collection during hospitalisation, e. Follow-up. Initial training sessions will be followed by more frequent follow-up of the study processess, possible complications, necessary adjustments of the protocol according to the initial experience (project manager Maja Drobnič Radobuljac) and re-training if necessary.

2.4.2. WP 2: Study and control group recruitment, data collection, patient follow-up.

Lead organisation: UPKL Participating organisations: KISLD and FERI

Objectives:

In this work package the investigators will focus on the involvement of patients and healthy adolescents. The work package includes capturing all patient data at Time 1 and tracking patients during hospitalization until discharge (Time 2) and recapturing data at Time 3 (Figure 2 of Study Protocol). On the control group side, only data at Time 1 will be captured (Figure 2 of Study Protocol). This work package has three main objectives: enrollment of hospitalized and healthy adolescents, data collection and follow-up.

Tasks:

T1: Enrollment of hospitalised adolescents. The Enrollment Kit and the Time1 Kit will be administered (see Figure 2 of Study Protocol), and the Time2 Kit will be administered during hospitalisation and at discharge.

T2: Enrollment of healthy adolescents (control group). The Enrollment Kit and the Time Kit1 will be administered (see Figure 2 of Study Protocol).

T3: Data collection. Data from hospitalised patients will be collected by administering the Enrollment, Time1, Time2 kits (see Figure 2 of Study Protocol). Adolescents in the control group will have the Enrollment and Time1 kits administered immediately on enrollment, no other data will be collected from these adolescents (see Figure 2 of Study Protocol). In the event that any of the adolescents approached appeared to be in need of help for self-injurious behaviour or other overt mental disorders, they will be referred for appropriate treatment.

T4: Tracking. Six and 18 months after the end of the hospitalization, the investigators will contact the patients again and administer the Time3 kit (see Figure 2 of Study Protocol). If any of the adolescents approached appear to need help for self-injurious behaviour or other overt mental disorders, they will be referred for appropriate treatment.

2.4.3. WP 3: Analysis of extracted materials, data entry and statistical analysis Lead organisation: UPKL, KISLD and FERI Participating organisations: UPKL, KISLD and FERI

Objectives:

The first objective is to identify the factors influencing the occurrence of the most threatening forms of self-injurious behaviour in adolescents.

The second aim is to assess the factors that influence change in risk of self-harm behaviour in the most at-risk adolescents.

The third objective is to develop an instrument (scale) for rapid assessment of short- and medium-term risk of self-harm in adolescents (ASHRS).

The details are in the Study Protocol.

Being tested
Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3, Columbia Suicide Severity Rating Scale (CSSRS), The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT), Experiences in Close Relationships-Relationship Structures (ECR-RS), Trauma Symptom Checklist for Children (TSCC)
Keywords
adolescent, deliberate self-harm, risk and protective factors, suicidal behavior, non-suicidal self-injury, risk assessment, attachment, genetics, epigenetics
Medical subject headings
Self-Injurious Behavior, Borderline Personality Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3Diagnostic test

    The questionnaires will cover general and demographic data, information on previous treatments, medication received, mental disorder at discharge (ICD), psychosocial situations (ICD), physical illnesses (ICD), COVID status (vaccinated, recovered, tested), use of psychoactive substances, history of self-harm, suicide attempts, school performance, experience with peers, sexual orientation and identity, residence, family composition, family history of mental disorders, self-harm and suicide attempts.

  • Columbia Suicide Severity Rating Scale (CSSRS)Diagnostic test

    The questionnaire is scientifically supported, has the most evidence of utility and efficacy, and is internationally accepted. It has been translated into more than 100 different languages, including Slovene. It is easy to use, suitable for all age groups and adapted for successful use outside the hospital setting, for example in schools, colleges, police, military and elsewhere. It contains 2 screening questions on suicidality and 4 more specific questions, 6 items in total.

    Posner K, Brown GK, Stanley B, et al. Am J Psychiatry 2011;168:1266-77.

  • The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT)Diagnostic test

    used for research purposes to assess the core characteristics of NSSI (form, frequency, function) as well as the secondary characteristics of NSSI (habituation, context of NSSI, perceived impact on life and treatment).

    Whitlock J, Exner-Cortens D, Purington A. Psychol Assess 2014;26:935-46.

  • Experiences in Close Relationships-Relationship Structures (ECR-RS)Diagnostic test

    Assesses the pattern of attachment to attachment figures (friend, romantic partner, mother, father) in adults and adolescents. The questionnaire has been officially translated into Slovene and used with several samples of Slovene adults and adolescents.

    Fraley RC, Waller NG, Brennan KA. J Pers Soc Psychol 2000;78:350-65.

  • Trauma Symptom Checklist for Children (TSCC)Diagnostic test

    The questionnaire helps to assess children's/adolescents' experiences of various traumatic experiences, such as physical or sexual violence, peer violence, loss, witnessing violent acts, natural disasters, etc. The questionnaire consists of 6 clinical scales (Anxiety, Depression, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), Sexual Concerns) and 2 validity scales. 6 clinical scales (Anxiety, Depressiveness, Anger, Post-traumatic Stress Symptom, Dissociativeness (two subscales), and 2 validity scales) are included.

    https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikotravmatiziranostiotrokinmladostnik. aspx

  • Personality Assessment Inventory-Adolescent (PAI-A)Diagnostic test

    An objective-type self-assessment questionnaire for assessing personality in adolescents. It has 264 items to be answered on a 4-point scale. 22 independent scales are obtained (Inconsistency, Rarity, Negative impression, Positive impression, Physical complaints, Anxiety, Anxiety-related disorders, Depressiveness, Mania, Paranoid, Schizophrenia, Borderline traits, Antisocial traits, Alcohol problems, Drug problems, Aggressiveness, Suicidal ideation, Stress, Lack of support, Refusal to deal, Dominance, Warmth).

    https://www.center-pds.si/Katalogtestov/Kliničnitesti/Vprašalnikzaocenoosebnosti-oblikazamladostnike-PAI-A.aspx

  • Inventory Of Statements About Self-Injury; ISASDiagnostic test

    A self-assessment questionnaire used for research purposes to assess the basic characteristics of NSSI (form, frequency, function, time to event). It also assesses the desire to stop. The questionnaire has been previously translated into Slovene and used in a population of adolescents with self-injurious behaviour.

    Glenn CR, Klonsky ED. One-year test-retest reliability of the Inventory of Statements about Self-Injury (ISAS). Assessment. 2011 Sep;18(3):375-8. doi: 10.1177/1073191111411669.

  • The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0Diagnostic test

    A short, user-friendly instrument that gives a quick impression of the expression of personality pathology. It consists of 12 items grouped into two higher-order domains: self-functioning and interpersonal functioning. Participants are asked to rate the 12 items on a four-point Likert scale ranging from 1 (completely false) to 4 (completely true). A total score (sum of all items), a self-functioning score (sum of items 1-6) and an interpersonal functioning score (sum of items 7-12) can be calculated. Satisfactory internal consistency and promising construct validity have been demonstrated. Sensitivity to change after three months of treatment was high.

    Weekers LC, Hutsebaut J, Kamphuis JH. The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning. Personal Ment Health 2019;13:3-14.

  • Borderline Personality Features Scale, BPFSC-11Diagnostic test

    The BPFS-C-11 includes BPD indicators such as affective instability, identity problems and negative attitudes. Responses to the items are on a 5-point Likert scale ranging from 'not at all true' to 'always true'. Studies have shown construct validity of interpretations of BPFS-C-11 scores through positive associations with other measures of BPD and positive associations with measures of BPD correlates, including emotional dysregulation. In a recent sample, the Cronbach's α over 4 years of follow-up was 0.86, 0.85, 0.86 and 0.90, respectively. The scale has been officially translated into Slovenian and will be used with the permission of the authors. It is intended for use by children and adolescents aged 9-11 years and consists of 11 items.

    Sharp, C., Steinberg, L., Temple, J., Newlin, E. An 11-Item Measure to Assess Borderline Traits in Adolescents: Refinement of the BPFSC Using IRT . Personality Disorders: Theory, Research, and Treatment 2014;5(1):70-78.

  • Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV)Other

    It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. The evaluation is efficient and takes less than five minutes. The nurse in charge of each patient completes the DASA-YV once a day.

    Dutch SG, Patil N. Validating a Measurement Tool to Predict Aggressive Behavior in Hospitalized Youth. J Am Psychiatr Nurses Assoc 2019;25:396-404.

  • Adolescent Self-Harm Risk Scale; ASHRSOther

    It's a professional assessment tool which provides a daily assessment of the risk of heteroaggression. This is the scale we developed for the present study. It will be used to assess and predict the short-term risk of self-harm behaviour during hospitalisation (assessment at admission) and the long-term risk after discharge (assessment at discharge).

  • Lifetime Incidence of Traumatic Events questionnaire (LITE)Diagnostic test

    Is a short checklist for screening and assessing the exposure to trauma in children and adolescents. It covers a broad range of potentially upsetting situations that can cause trauma to children and adolescents, such as a car accident, fire, death of a family member, exposure to threats, sexual assault, or witnessing violence. The questionnaire had been validated on a Slovene population of children and adolesscents.

    Greenwald R, Rubin A. Assessment of posttraumatic symptoms in children:

    development and preliminary validation of parent and child scales. Res Soc Work Pract. (1999) 9:61-75. doi: 10.1177/104973159900900105 Uršicˇ K, Bucik V, Klemencˇ icˇ S, Bratina N, Battelino T, Dovcˇ K and Drobnicˇ Radobuljac M (2021) Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia. Front. Psychiatry 12:665315. doi: 10.3389/fpsyt.2021.665315

  • Genetic methodsGenetic

    DNA isolation, Sequencing, Libraries preparation, Analisys; Bioinformatics (Base Calling, Variant Calling, Quantification and evaluation of short tandem repetitions, Methylation sites detection).

Study groups in NCT05765864
Study groupRoleWhat they receive
PatientsThe Enrollment Kit and Time1 Kit will be administered at enrollment, Time2 Kit will be administered before discharge and Time 3 kit after 6 and 18 months post hospitalization (see Detailed description and Study Protocol). The interventions will be Treatment as usual.
Receives: Diagnostic Test: Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3; Diagnostic Test: Columbia Suicide Severity Rating Scale (CSSRS); Diagnostic Test: The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT); Diagnostic Test: Experiences in Close Relationships-Relationship Structures (ECR-RS); Diagnostic Test: Trauma Symptom Checklist for Children (TSCC); Diagnostic Test: Personality Assessment Inventory-Adolescent (PAI-A); Diagnostic Test: Inventory Of Statements About Self-Injury; ISAS; Diagnostic Test: The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0; Diagnostic Test: Borderline Personality Features Scale, BPFSC-11; Other: Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV); Other: Adolescent Self-Harm Risk Scale; ASHRS; Diagnostic Test: Lifetime Incidence of Traumatic Events questionnaire (LITE); Genetic: Genetic methods
ControlsThe Enrollment Kit and the Time Kit1 will be administered (see Detailed description and Study Protocol).
Receives: Diagnostic Test: Enrollment questionnaire, General questionnaire1, General questionnaire2, General questionnaire3; Diagnostic Test: Columbia Suicide Severity Rating Scale (CSSRS); Diagnostic Test: The Brief Non-Suicidal Self-Injury Assessment Tool (B-NSSI-AT); Diagnostic Test: Experiences in Close Relationships-Relationship Structures (ECR-RS); Diagnostic Test: Trauma Symptom Checklist for Children (TSCC); Diagnostic Test: Personality Assessment Inventory-Adolescent (PAI-A); Diagnostic Test: Inventory Of Statements About Self-Injury; ISAS; Diagnostic Test: The Level of Personality Functioning Scale-Brief Form 2.0; LPFSBF 2.0; Diagnostic Test: Borderline Personality Features Scale, BPFSC-11; Other: Dynamic Appraisal of Situational Aggression-Youth Version (DASA-YV); Other: Adolescent Self-Harm Risk Scale; ASHRS; Diagnostic Test: Lifetime Incidence of Traumatic Events questionnaire (LITE); Genetic: Genetic methods

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Self-harm incident

    Registered incident of self-harm

    Measured: "through study completion, an average of 1 year"

  2. Prevented self-harm incident

    Registration of an intended self-harm prevented by hospital staff (nurses)

    Measured: "up to 12 weeks"

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2023
  2. Study start23 Mar 2023
  3. Primary completionOct 2025 (estimated)
  4. Study completionOct 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Other
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05765864
Sponsor's protocol ID
Adolescent self-harm
Acronym
SH-MARA
Status last verified
Mar 2025
First submitted
12 Feb 2023
Last updated
28 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, Evans AC, Rapoport JL. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci. 1999 Oct;2(10):861-3. doi: 10.1038/13158. No abstract available.

    PubMed 10491603
  • Spear LP. Adolescent neurodevelopment. J Adolesc Health. 2013 Feb;52(2 Suppl 2):S7-13. doi: 10.1016/j.jadohealth.2012.05.006.

    PubMed 23332574
  • Steinberg L, Morris AS. Adolescent development. Annu Rev Psychol. 2001;52:83-110. doi: 10.1146/annurev.psych.52.1.83.

    PubMed 11148300
  • Stoep AV, McCauley E, Flynn C, Stone A. Thoughts of death and suicide in early adolescence. Suicide Life Threat Behav. 2009 Dec;39(6):599-613. doi: 10.1521/suli.2009.39.6.599.

    PubMed 20121323
  • Radobuljac MD, Bratina NU, Battelino T, Tomori M. Lifetime prevalence of suicidal and self-injurious behaviors in a representative cohort of Slovenian adolescents with type 1 diabetes. Pediatr Diabetes. 2009 Nov;10(7):424-31. doi: 10.1111/j.1399-5448.2009.00501.x. Epub 2009 Apr 8.

    PubMed 19490494
  • Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. J Child Psychol Psychiatry. 2006 Mar-Apr;47(3-4):372-94. doi: 10.1111/j.1469-7610.2006.01615.x.

    PubMed 16492264
  • SURS. Slovenija: Statistični Urad Republike Slovenije; 2021.

  • Wilkinson P, Goodyer I. Non-suicidal self-injury. Eur Child Adolesc Psychiatry. 2011 Feb;20(2):103-8. doi: 10.1007/s00787-010-0156-y. Epub 2011 Jan 11.

    PubMed 21222215
  • Surveillance report 2016 - Self-harm in over 8s: short-term management and prevention of recurrence (2004) NICE guideline CG16 and Self-harm in over 8s: long term management (2011) NICE guideline CG133 [Internet]. London: National Institute for Health and Care Excellence (NICE); 2016 Sep 30. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK552073/

    PubMed 31891461
  • Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition ed. Arlington, VA: American Psychiatric Association; 2013.

  • Favazza AR, Conterio K. Female habitual self-mutilators. Acta Psychiatr Scand. 1989 Mar;79(3):283-9. doi: 10.1111/j.1600-0447.1989.tb10259.x.

    PubMed 2711856
  • Favazza AR. Nonsuicidal self-injury: How categorization guides treatment. Current Psychiatry 2012;11(3):21-5.

  • Tomori M, Zalar B, Plesnicar BK. Gender differences in psychosocial risk factors among Slovenian adolescents. Adolescence. 2000 Autumn;35(139):431-43.

    PubMed 11130589
  • Žerjav Ž, Drobnič Radobuljac M. Medicinski Razgledi 2019;58:417-27.

  • Kiric B, Leben Novak L, Lusicky P, Drobnic Radobuljac M. Suicidal Behavior in Emergency Child and Adolescent Psychiatric Service Users Before and During the 16 Months of the COVID-19 Pandemic. Front Psychiatry. 2022 May 11;13:893040. doi: 10.3389/fpsyt.2022.893040. eCollection 2022.

    PubMed 35633784

Questions about this trial

What is this clinical trial studying?

An observational study of Self-harm and Personality Disorder, Borderline, run by University of Ljubljana, Faculty of Medicine at 2 sites in Slovenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maja Drobnič Radobuljac (015874840 ext. +386, maja.radobuljac@psih-klinika.si), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Self-harm incident (time frame: "through study completion, an average of 1 year"). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05765864, which also lists 88 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in